Impact of everolimus on Japanese patients with advanced pancreatic neuroendocrine neoplasms

Lingaku Lee, Tetsuhide Ito, Hisato Igarashi, Keijiro Ueda, Takashi Fujiyama, Ken Kawabe, Yoshihiro Ogawa

研究成果: ジャーナルへの寄稿記事

4 引用 (Scopus)

抄録

Background: Although everolimus has become a key therapeutic agent in patients with advanced pancreatic neuroendocrine neoplasms (PNEN), its efficacy and safety in clinical practice remains unclear. Methods: Forty-seven patients with advanced PNEN treated with everolimus were reviewed retrospectively. To evaluate the safety of everolimus as a long-term treatment, the patients were divided into two groups according to treatment duration: group A, ≤1 year (n = 21); group B, >1 year (n = 26). Results: Among 42 patients with pancreatic neuroendocrine tumors (PNET), the median progression-free survival, overall survival, and objective response rate were 27.5 months, 60.8 months, and 19.0%, respectively. Two patients with pancreatic neuroendocrine carcinomas (PNEC) with lower Ki-67 index and well-differentiated tumors showed favorable responses. More patients in group A discontinued everolimus owing to adverse drug reactions (ADRs) than in group B. The median relative dose intensity was significantly lower in group B than group A (P = 0.045), whereas the drug interruption rate was significantly higher in group B than group A (P < 0.001). Conclusions: Everolimus showed significant clinical benefit in Japanese patients with advanced PNEN. Prevention of severe ADRs by appropriate dose reduction and interruption is necessary for a long-term continuation of everolimus.

元の言語英語
ページ(範囲)95-102
ページ数8
ジャーナルJournal of Hepato-Biliary-Pancreatic Sciences
24
発行部数2
DOI
出版物ステータス出版済み - 2 1 2017

Fingerprint

Pancreatic Neoplasms
Drug-Related Side Effects and Adverse Reactions
Safety
Neuroendocrine Carcinoma
Neuroendocrine Tumors
Proxy
Disease-Free Survival
Everolimus
Therapeutics
Survival
Pharmaceutical Preparations
Neoplasms

All Science Journal Classification (ASJC) codes

  • Surgery
  • Hepatology

これを引用

Impact of everolimus on Japanese patients with advanced pancreatic neuroendocrine neoplasms. / Lee, Lingaku; Ito, Tetsuhide; Igarashi, Hisato; Ueda, Keijiro; Fujiyama, Takashi; Kawabe, Ken; Ogawa, Yoshihiro.

:: Journal of Hepato-Biliary-Pancreatic Sciences, 巻 24, 番号 2, 01.02.2017, p. 95-102.

研究成果: ジャーナルへの寄稿記事

Lee, Lingaku ; Ito, Tetsuhide ; Igarashi, Hisato ; Ueda, Keijiro ; Fujiyama, Takashi ; Kawabe, Ken ; Ogawa, Yoshihiro. / Impact of everolimus on Japanese patients with advanced pancreatic neuroendocrine neoplasms. :: Journal of Hepato-Biliary-Pancreatic Sciences. 2017 ; 巻 24, 番号 2. pp. 95-102.
@article{509660856bee4ae2920e5ec7e27a74e2,
title = "Impact of everolimus on Japanese patients with advanced pancreatic neuroendocrine neoplasms",
abstract = "Background: Although everolimus has become a key therapeutic agent in patients with advanced pancreatic neuroendocrine neoplasms (PNEN), its efficacy and safety in clinical practice remains unclear. Methods: Forty-seven patients with advanced PNEN treated with everolimus were reviewed retrospectively. To evaluate the safety of everolimus as a long-term treatment, the patients were divided into two groups according to treatment duration: group A, ≤1 year (n = 21); group B, >1 year (n = 26). Results: Among 42 patients with pancreatic neuroendocrine tumors (PNET), the median progression-free survival, overall survival, and objective response rate were 27.5 months, 60.8 months, and 19.0{\%}, respectively. Two patients with pancreatic neuroendocrine carcinomas (PNEC) with lower Ki-67 index and well-differentiated tumors showed favorable responses. More patients in group A discontinued everolimus owing to adverse drug reactions (ADRs) than in group B. The median relative dose intensity was significantly lower in group B than group A (P = 0.045), whereas the drug interruption rate was significantly higher in group B than group A (P < 0.001). Conclusions: Everolimus showed significant clinical benefit in Japanese patients with advanced PNEN. Prevention of severe ADRs by appropriate dose reduction and interruption is necessary for a long-term continuation of everolimus.",
author = "Lingaku Lee and Tetsuhide Ito and Hisato Igarashi and Keijiro Ueda and Takashi Fujiyama and Ken Kawabe and Yoshihiro Ogawa",
year = "2017",
month = "2",
day = "1",
doi = "10.1002/jhbp.418",
language = "English",
volume = "24",
pages = "95--102",
journal = "Journal of Hepato-Biliary-Pancreatic Sciences",
issn = "1868-6974",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Impact of everolimus on Japanese patients with advanced pancreatic neuroendocrine neoplasms

AU - Lee, Lingaku

AU - Ito, Tetsuhide

AU - Igarashi, Hisato

AU - Ueda, Keijiro

AU - Fujiyama, Takashi

AU - Kawabe, Ken

AU - Ogawa, Yoshihiro

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Background: Although everolimus has become a key therapeutic agent in patients with advanced pancreatic neuroendocrine neoplasms (PNEN), its efficacy and safety in clinical practice remains unclear. Methods: Forty-seven patients with advanced PNEN treated with everolimus were reviewed retrospectively. To evaluate the safety of everolimus as a long-term treatment, the patients were divided into two groups according to treatment duration: group A, ≤1 year (n = 21); group B, >1 year (n = 26). Results: Among 42 patients with pancreatic neuroendocrine tumors (PNET), the median progression-free survival, overall survival, and objective response rate were 27.5 months, 60.8 months, and 19.0%, respectively. Two patients with pancreatic neuroendocrine carcinomas (PNEC) with lower Ki-67 index and well-differentiated tumors showed favorable responses. More patients in group A discontinued everolimus owing to adverse drug reactions (ADRs) than in group B. The median relative dose intensity was significantly lower in group B than group A (P = 0.045), whereas the drug interruption rate was significantly higher in group B than group A (P < 0.001). Conclusions: Everolimus showed significant clinical benefit in Japanese patients with advanced PNEN. Prevention of severe ADRs by appropriate dose reduction and interruption is necessary for a long-term continuation of everolimus.

AB - Background: Although everolimus has become a key therapeutic agent in patients with advanced pancreatic neuroendocrine neoplasms (PNEN), its efficacy and safety in clinical practice remains unclear. Methods: Forty-seven patients with advanced PNEN treated with everolimus were reviewed retrospectively. To evaluate the safety of everolimus as a long-term treatment, the patients were divided into two groups according to treatment duration: group A, ≤1 year (n = 21); group B, >1 year (n = 26). Results: Among 42 patients with pancreatic neuroendocrine tumors (PNET), the median progression-free survival, overall survival, and objective response rate were 27.5 months, 60.8 months, and 19.0%, respectively. Two patients with pancreatic neuroendocrine carcinomas (PNEC) with lower Ki-67 index and well-differentiated tumors showed favorable responses. More patients in group A discontinued everolimus owing to adverse drug reactions (ADRs) than in group B. The median relative dose intensity was significantly lower in group B than group A (P = 0.045), whereas the drug interruption rate was significantly higher in group B than group A (P < 0.001). Conclusions: Everolimus showed significant clinical benefit in Japanese patients with advanced PNEN. Prevention of severe ADRs by appropriate dose reduction and interruption is necessary for a long-term continuation of everolimus.

UR - http://www.scopus.com/inward/record.url?scp=85013287858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013287858&partnerID=8YFLogxK

U2 - 10.1002/jhbp.418

DO - 10.1002/jhbp.418

M3 - Article

C2 - 27926987

AN - SCOPUS:85013287858

VL - 24

SP - 95

EP - 102

JO - Journal of Hepato-Biliary-Pancreatic Sciences

JF - Journal of Hepato-Biliary-Pancreatic Sciences

SN - 1868-6974

IS - 2

ER -